Zhou Qiufeng, Yue Shuanglei, Cheng Ye, Jin Ju, Xu Haimiao
Anji County People's Hospital, Huzhou 313000, Zhejiang, China.
Zhejiang Cancer Hospital, Hangzhou 310000, Zhejiang, China.
Exp Toxicol Pathol. 2017 Oct 2;69(8):575-579. doi: 10.1016/j.etp.2017.05.003. Epub 2017 May 25.
Medullary thyroid carcinoma (MTC), defined as a malignant tumour with C-cell differentiation, is of neuroendocrine origin and is characterized by the synthesis and secretion of calcitonin (CT). MTC without CT secretion has been reported on rare occasions. The purpose of this study was to evaluate the histological, immunohistochemical, and molecular pathologic features as well as the clinical significance of non-secretory MTC (NCR-MTC).
A retrospective analysis of patients with NCR-MTC was performed. The clinical features of NCR-MTC, including age, gender, tumour size and number, clinical signs of hypocalcaemia and diarrhoea, and the presence of lymph node metastasis, as well as the pathologic features of the disease, including tumour morphology, presence of neuroendocrine structures, capsular invasion, and immunohistochemical expression and presence of mutations in the RET gene, were evaluated.
Nineteen patients with NCR-MTC were identified among 158 patients with MTC, resulting in a prevalence rate of 12.02%. Patients with NCR-MTC typically had masses less than 1cm in size (73.7%, 14/19). Hypocalcaemia was not present in 94.7% (18/19) of patients. While 42.1% (8/19) of patients with NCR-MTC did not have amyloid deposits, only 18% (25/139) of patients with secretory MTC did not have such deposits. While 95.7% (133/139) of the control group of patients with secretory MTC had neuroendocrine tumour structure, only 84.2% (16/19) of the patients with NCR-MTC had this type of tumour structure. Patients with NCR-MTC were also less likely to have vascular tumour thrombus, lymph node metastasis or thyroid capsular invasion. With regard to immunohistochemistry, CT expression was mostly negative, and carcinoembryonic antigen (CEA) expression was positive in 21.1% (4/19) of patients with NCR-MTC, while only 5.8% (8/139) of patients in the control group had positive CEA expression.
The prevalence of NCR-MTC was low (12.02%). This type of tumour was smaller in size and more differentiated. Compared with the control group, relatively few patients had obvious symptoms, hypocalcaemia, lymph node metastasis, thyroid capsular or vascular invasion, or tumours with amyloid or neuroendocrine tumour structure.
甲状腺髓样癌(MTC)被定义为具有C细胞分化的恶性肿瘤,起源于神经内分泌,其特征是合成和分泌降钙素(CT)。罕见情况下有不分泌CT的MTC报道。本研究的目的是评估非分泌型MTC(NCR-MTC)的组织学、免疫组化和分子病理学特征以及临床意义。
对NCR-MTC患者进行回顾性分析。评估NCR-MTC的临床特征,包括年龄、性别、肿瘤大小和数量、低钙血症和腹泻的临床体征以及淋巴结转移情况,以及该疾病的病理特征,包括肿瘤形态、神经内分泌结构的存在、包膜侵犯、RET基因的免疫组化表达和突变情况。
在158例MTC患者中识别出19例NCR-MTC患者,患病率为12.02%。NCR-MTC患者的肿块通常小于1cm(73.7%,14/19)。94.7%(18/19)的患者无低钙血症。NCR-MTC患者中42.1%(8/19)没有淀粉样蛋白沉积,而分泌型MTC患者中只有18%(25/139)没有此类沉积。分泌型MTC对照组患者中95.